Hives treatment developer Third Harmonic prices upsized $185M IPO

Sep. 14, 2022 8:00 PM ETThird Harmonic Bio, Inc. (THRD)By: Val Kennedy, SA News Editor

IPO Initial Public Offering

Mikko Lemola

Hives treatment developer Third Harmonic Bio (THRD) has priced its upsized $185M initial public offering.

The biotech company said it now plans to offer 10.9M shares at $17 per share. Underwriters will be granted a 30-day option

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.